Ophthalmic Business News

Melt Pharmaceuticals secured $24 million in Series B preferred stock financing from new and existing investors, according to a press release.

Patients with presbyopia achieved visual acuity improvement with LNZ100 in the phase 3 CLARITY safety and efficacy trials, according to a press release from Lenz Therapeutics.

ViaLase has secured approximately $40 million in Series C financing to drive the continued development of the company’s femtosecond laser for the treatment of glaucoma, according to a press release.

Viatris is launching the first commercially available, FDA-approved eyedrop for the reversal of dilation, according to a press release.

The first quarter of 2024 has come to a close, but Healio’s ophthalmology meeting news coverage is just getting started.

The number one financial goal for most physicians is getting to a comfortable retirement on their own timeline and with the lifestyle they want.

In this Healio Video Perspective, John A. Hovanesian, MD, FACS, and Jim Mazzo preview the latest episode of the Eyeluminaries podcast.

CMS has assigned a permanent J-code for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric Bio.

Dosing is complete in the first cohort of the phase 1/2 clinical trial of OPGx-LCA5 for the treatment of Leber congenital amaurosis, according to a press release from Opus Genetics.